Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02838316 · ClinicalTrials.gov registry record · Phase 1

Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR) for Tongue Dysphagia

A Phase 1 study of Oropharyngeal Dysphagia, sponsored by Peter Belafsky, MD.

Active
Registry status
Phase 1
Development phase
18
Enrollment target
1
Study location

NCT02838316 is a Phase 1 study of Oropharyngeal Dysphagia that is active but no longer recruiting, run by Peter Belafsky, MD. The registered enrollment target is 18 participants, below the 108-participant average among 7 other Oropharyngeal Dysphagia trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02838316, a Phase 1 study of Oropharyngeal Dysphagia, is active but no longer recruiting, sponsored by Peter Belafsky, MD.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
18 participants
Enrollment target
1
Study location

Study Summary

The primary objective of this study is to evaluate the safety of Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR) during the 12 months following treatment of tongue dysphagia in male and female patients who have undergone surgery and/or chemo- and/or radiotherapy for squamous cell cancer of the oropharynx.

Conditions Studied

Oropharyngeal Dysphagia

Interventions

  • DRUG Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR)

Study Locations (1)

California

  • UC Davis Medical Center, Department of Otolaryngology, Head and Neck Surgery - Sacramento

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2017-05-24
Est. Completion 2026-12
Phase Phase 1

Sponsor

Peter Belafsky, MD

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02838316

The ClinicalTrials.gov registry entry for NCT02838316 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 108-participant average among 7 other Oropharyngeal Dysphagia trials with a reported enrollment target (83% lower). The listed sponsor is Peter Belafsky, MD, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Oropharyngeal Dysphagia appearing as the primary indexed condition, and to 1 intervention - of which Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR) is the first listed.

NCT02838316 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT02838316 about?

NCT02838316 is a clinical study titled "Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR) for Tongue Dysphagia". The primary objective of this study is to evaluate the safety of Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR) during the 12 months following treatment of tongue dysphagia in male and female patients who have undergone surgery and/or chemo- and/or radiotherapy for squamous ...

What is the current status of trial NCT02838316?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2017-05-24. Estimated completion is 2026-12.

What conditions does trial NCT02838316 study?

This clinical trial studies the following conditions: Oropharyngeal Dysphagia.

What interventions are being tested in trial NCT02838316?

The interventions under investigation include: Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR) (DRUG).

Who is sponsoring clinical trial NCT02838316?

This trial is sponsored by Peter Belafsky, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02838316 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Oropharyngeal Dysphagia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Oropharyngeal Dysphagia

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.